While inhaled chemotherapy has been evaluated for many decades, most clinical trials failed due to various reasons, that may include poor dosage form design disregarding physiological structure of lungs, minimal attention to maximize tumor penetration, need to administer large doses, issues related to safety of medical staff due to aerosol contamination. Development of new technologies such as controlled release dry-powder inhalers, smart inhalers, and targeted deposition have shown promise in navigating through challenges associated with localized lung cancer treatment. Development of a combination approach utilizing controlled release nanomedicine, and an optimized inhalation delivery platform has shown promise in lung cancer therapeutics. In this presentation, the speaker will provide an insight into current developmental domain for inhaled therapeutics for lung cancer, including novel delivery systems, new delivery devices, and novel formulation and targeting approaches. The speaker will also present a preclinical/clinical case-study highlighting the impact of combining nanomedicine and delivery platforms.
Learning Objectives:
Understand lung physiology, and development of deep lung tumors
Demonstrate the feasibility and relevance of inhaled therapeutics for lung cancer treatment
Understand impact of novel delivery devices and platforms for delivery of therapeutics in deep lung regions
